<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812032</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT No: 2007-003186-40</org_study_id>
    <nct_id>NCT00812032</nct_id>
  </id_info>
  <brief_title>Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic Patients</brief_title>
  <acronym>DM-ASA 001</acronym>
  <official_title>Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of low dose aspirin appears to be substantially lower in diabetic patients,
      compared to patients without diabetes. The aim of the investigators study is to test the
      laboratory response to different dosing of aspirin in type 2 Diabetes Mellitus. The
      investigators will compare the regular dose of 75mg once daily to 75 mg twice daily or to 320
      mg once daily. The hypothesis of the study is that twice daily dosing of aspirin may improve
      the response to aspirin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>An exploratory study with three co-primary response variables which are directly related to platelet COX-1 inhibition: arachidonic acid-induced platelet aggregation in whole blood and PRP and in the Cone-and-Plate(let) Assay (CPA)</measure>
    <time_frame>12 or 24 hours after last dose of Aspirin</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Indirectly COX-related platelet aggregation induced by collagen or ADP, and thromboxane metabolite excretion.</measure>
    <time_frame>12 or 24 hours after last dose of aspirin</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>75 mg per day versus 75 mg twice daily and 320mg once daily</description>
    <other_name>Trombyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>crossover study with three dosages: 75 mg once daily, 75 mg twice daily, 320 mg once daily.</description>
    <other_name>Trombyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 DM with micro- or macroangiopathy.

          -  HbA1c 6-9 % (Mono-S method).

          -  Need for, or already on-going aspirin treatment.

          -  Age 50-75 years

          -  Antecubital forearm veins allowing technically good sampling for platelet studies

        Exclusion Criteria:

          -  Diet controlled DM.

          -  Acute ischemic stroke, acute coronary syndrome, (myocardial infarction or unstable
             angina pectoris), or revascularization by PCI or by-pass surgery within the last 6
             months.

          -  Acute or chronic kidney disease (P-cystatin C within the reference interval)

          -  Acute or chronic liver disease (ALAT â‰¤2 times the upper reference value).

          -  A history of gastric or duodenal ulcer disease.

          -  Need for treatment with anticoagulants, clopidogrel, NSAID's, or thiazolidinediones.

          -  Thrombocytopenia (platelet count &lt;150 x 109/L)

          -  Anticipated need for alteration of concomitant drug therapy during the course of the
             study.

          -  Enrollment in another clinical study.

          -  Contraindication(s) to aspirin treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Hjemdahl, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Clinical pharmacology Unit, Karolinska University Hospital, Solna.</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <last_update_submitted>July 30, 2010</last_update_submitted>
  <last_update_submitted_qc>July 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Paul Hjemdahl</name_title>
    <organization>Dept Medicine Solna, Clinical Pharmacology Unit, Karolinska Institute, Stockholm, Sweden</organization>
  </responsible_party>
  <keyword>NIDDM</keyword>
  <keyword>Aspirin</keyword>
  <keyword>platelet inhibition</keyword>
  <keyword>Aspirin treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

